CAPTRUST Financial Advisors
YMAB

CAPTRUST Financial Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-154
Closed -$2K – 4117
2022
Q2 		$2K Hold
154
– – ﹤0.01% 4528
2022
Q1 		$2K Buy
+154
New +$1.58K ﹤0.01% 4561
2021
Q2 		– Sell
-40
Closed -$1K – 4677
2021
Q1 		$1K Buy
+40
New +$1.64K ﹤0.01% 4254

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

CAPTRUST Financial Advisors's YMAB Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q3 2022, closing a stake of 154 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in YMAB in Q1 2021 and held it in 3 quarters. The position peaked at $2K in Q2 2022. 100 funds tracked by Wall St. Rank hold YMAB as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Y-mAbs Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 154 Y-mAbs Therapeutics shares in Q3 2022, an estimated $2K.
  • CAPTRUST Financial Advisors first reported a position in Y-mAbs Therapeutics in Q1 2021 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's Y-mAbs Therapeutics position peaked at $2K in Q2 2022.
  • 100 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.